AKT1 and Hyperglycemia: Although an increased risk of hyperglycaemia has also been described individually for inhibitors of PI3K, AKT and mTOR in phase I–II clinical trials, the severity and complications of hyperglycaemia caused by PAM pathway inhibitors as a whole, together with its appropriate management, has not been studied together.